Cargando…

Perspectives on the FDA Draft Guidances for Use of Adipose Tissue

Detalles Bibliográficos
Autores principales:	Johnson, Martin L., Johnson, Logan, Mahabir, Raman C., Bernard, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434492/ https://www.ncbi.nlm.nih.gov/pubmed/28333305 http://dx.doi.org/10.1093/asj/sjx049

Ejemplares similares

FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology
por: Russell, Elizabeth S., et al.
Publicado: (2023)

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”
por: de Vlieger, Jon S. B., et al.
Publicado: (2019)

Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
por: Harrison, John E.
Publicado: (2018)

New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19
por: Turner, J. Rick
Publicado: (2020)

Rediscovering FDA Websites
por: Navarro, Robert P.
Publicado: (2012)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures
por: Bradley, Clare
Publicado: (2006)

Paxlovid(TM) Information From FDA and Guidance for AES Members
por: Cokley, Jon A., et al.
Publicado: (2022)

Guidance to Best Tools and Practices for Systematic Reviews
por: Kolaski, Kat, et al.
Publicado: (2023)

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
por: Arpinelli, Fabio, et al.
Publicado: (2006)

Adipose Tissue Inflammation
por: Gómez-Ambrosi, Javier
Publicado: (2023)

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
por: Dy, Grace K., et al.
Publicado: (2019)

While We’re at It, Let’s Whack the FDA
por: Chabner, Bruce A.
Publicado: (2016)

The 2014 FDA assessment of commercial fish: practical considerations for improved dietary guidance
por: McGuire, Jennifer, et al.
Publicado: (2016)

Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing
por: Cornetta, Kenneth, et al.
Publicado: (2022)

Manifestations of Adipose Tissue Dysfunction
por: Abate, Nicola, et al.
Publicado: (2013)

Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials
por: Yu, Jeffrey C., et al.
Publicado: (2022)

Understanding the new FDA pregnancy and lactation labeling rules()
por: Blattner, Collin M., et al.
Publicado: (2016)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

VARC consensus report: the FDA perspective(†)
por: Hillebrenner, Matthew G., et al.
Publicado: (2011)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alpha-ketoglutarate for adipose tissue rejuvenation
por: Tian, Qiyu, et al.
Publicado: (2020)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Retraction of WHO guidance on opioid use
Publicado: (2020)

FDA, CE mark or something else?—Thinking fast and slow
por: Mishra, Sundeep
Publicado: (2017)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare
por: Gillette, Michael, et al.
Publicado: (2020)

The proposed rule of the FDA banning menthol as a characterizing flavor
por: Romeo-Stuppy, Kelsey
Publicado: (2022)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue
por: Qiu, Yan, et al.
Publicado: (2018)

Let there be Guidance!!!
por: Kulkarni, Atul P
Publicado: (2020)

Synchrony 2022: Roundtable Discussion on the Pathways and the Challenges of Getting Medications FDA Approved
por: Belfort, Gabriel, et al.
Publicado: (2023)

Adipogenesis: It Is Not Just Lipid That Comprises Adipose Tissue
por: Dodson, Michael V., et al.
Publicado: (2013)

DNA Methylation in Adipose Tissue and Metabolic Syndrome
por: Panchal, Sunil K., et al.
Publicado: (2020)

Adipose Tissue-Derived Mesenchymal Stem Cells
por: Bunnell, Bruce A.
Publicado: (2021)

Adipose Tissue Metabolism in Response to Food Intake
por: Carrillo, Andres E., et al.
Publicado: (2023)

Hip Metallosis and Corrosion—A Million Harmed Due to FDA Inaction
por: Tower, Stephen
Publicado: (2019)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o8krpn6n14bk5vf7c9ki4otujc